RNF2 mediates pulmonary fibroblasts activation and proliferation by regulating mTOR and p16-CDK4-Rb1 signaling pathway

Pan, Linxin; Hu, Ying; Qian, Cheng; Yao, Yan; Wang, Shuxian; Shi, Wanrong; Xu, Tao

doi:10.1007/s00011-022-01617-8

Cited by 3 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Meanwhile, MB cells transfected with lentish UHRF1 showed increased p16 expression and location shift of CDK4 [20] . P16and CDk4 loss stimulated cell proliferation, and accelerated cell cycle progression in vitro and in vivo [34,35] . Consequently, Zhang et al indicated the hight expression of UHRF1 may promote cell proliferation in MB [20] .…”

Section: Discussionmentioning

confidence: 95%

Evaluation of expression of UHRF1 and its prognostic and clinicopathological value in human malignancies: A Systematic Review and Meta-analysis

Shu

Liu

Mou

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: The mortality and recurrence of patients with cancer is of high prevalence. Ubiquitin-like with plant homeodomain (PHD) and RING finger domains 1 (UHRF1) is a promising nuclear protein gene. There is increasing evidence that UHRF1 is abnormally expressed in various tumors and is associated with cancer prognosis. This study was designed to identify the prognostic value of UHRF1 in human malignancies. Methods: we searched electronic databases up to February 18, 2023, including PubMed, Cochrane Library, Embase, MEDLINE, and Web of Science. Eligible studies that evaluated the clinicopathological and prognostic role of UHRF1 in patients with malignant tumors were included. The pooled odds ratios (ORs) and the hazard ratios (HRs) were calculated to assess the role of UHRF1 using Stata/SE 14.1 software. Results: 10 studies included a total of 1461 patients on cancer patients were incorporated into the present meta-analysis. The combined results revealed that high expression of UHRF1 was significantly associated with unfavorable overall survival (OS) (HR=2.01, 95% CI: 1.23-3.29, P=0.005), worse disease free survival(DFS) (HR=1.86, 95% CI: 1.34-2.60, P=0.0002) in a variety of cancers. In additional, the increase in UHRF1 expression was also closely correlated with poor clinical stage (OR = 2.37, 95% CI: 1.59-3.51), lymph node metastasis (OR = 2.86, 95% CI: 1.97-4.16), and tumor recurrence (OR = 3.62, 95% CI: 2.30-5.28) in patients with cancer. Furthermore, the expression datasets of UHRF1 in human malignancies and paired normal tissues were downloaded from Gene Expression Profiling Interactive Analysis(GEPIA) showed that the expression level of UHRF1 was higher in most tumor tissues than in the corresponding normal tissues, which predicted a worse prognosis.The data analysis in Kaplan-meier Plotter also confirmed that patients with UHRF1 upregulation had a worse prognosis. Conclusions: UHRF1 may actas a valuable prognostic biomarker and a potential therapeutic target for patients with cancers.

show abstract

Section: Discussionmentioning

confidence: 95%

Evaluation of expression of UHRF1 and its prognostic and clinicopathological value in human malignancies: A Systematic Review and Meta-analysis

Shu

Liu

Mou

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…These proteins play critical roles in controlling cell proliferation and suppressing tumorigenesis. P16 functions as a cyclin-dependent kinase inhibitor, specifically targeting cyclin-dependent kinase 4 (CDK4) and CDK6, thereby preventing their interaction with cyclin D and inhibiting the phosphorylation of retinoblastoma protein (Rb)[ 8 – 10 ]. This leads to cell cycle arrest at the G1 phase and halts cell proliferation.…”

Section: Introductionmentioning

confidence: 99%

CDKN2A promoter methylation enhances self-renewal of glioblastoma stem cells and confers resistance to carmustine

Wang,

Xi,

Zhao

et al. 2024

Mol Biol Rep

View full text Add to dashboard Cite

Background Glioblastoma, a highly aggressive form of brain cancer, poses significant challenges due to its resistance to therapy and high recurrence rates. This study aimed to investigate the expression and functional implications of CDKN2A, a key tumor suppressor gene, in glioblastoma cells, building upon the existing background of knowledge in this field. Method Quantitative reverse transcription PCR (qRT-PCR) analysis was performed to evaluate CDKN2A expression in U87 glioblastoma cells compared to normal human astrocytes (NHA). CDKN2A expression levels were manipulated using small interfering RNA (siRNA) and CDKN2A overexpression vector. Cell viability assays and carmustine sensitivity tests were conducted to assess the impact of CDKN2A modulation on glioblastoma cell viability and drug response. Sphere formation assays and western blot analysis were performed to investigate the role of CDKN2A in glioblastoma stem cell (GSC) self-renewal and pluripotency marker expression. Additionally, methylation-specific PCR (MSP) assays and demethylation treatment were employed to elucidate the mechanism of CDKN2A downregulation in U87 cells. Result CDKN2A expression was significantly reduced in glioblastoma cells compared to NHA. CDKN2A overexpression resulted in decreased cell viability and enhanced sensitivity to carmustine treatment. CDKN2A inhibition promoted self-renewal capacity and increased pluripotency marker expression in U87 cells. CDKN2A upregulation led to elevated protein levels of p16INK4a, p14ARF, P53, and P21, which are involved in cell cycle regulation. CDKN2A downregulation in U87 cells was associated with high promoter methylation, which was reversed by treatment with a demethylating agent. Conclusion Our findings demonstrate that CDKN2A downregulation in glioblastoma cells is associated with decreased cell viability, enhanced drug resistance, increased self-renewal capacity, and altered expression of pluripotency markers. The observed CDKN2A expression changes are mediated by promoter methylation. These results highlight the potential role of CDKN2A as a therapeutic target and prognostic marker in glioblastoma.

show abstract

Immune mechanisms and novel therapies for idiopathic pulmonary fibrosis

Gao,

Zhai

et al. 2024

Pharmaceutical Science Advances

View full text Add to dashboard Cite

RNF2 mediates pulmonary fibroblasts activation and proliferation by regulating mTOR and p16-CDK4-Rb1 signaling pathway

Cited by 3 publications

References 33 publications

Evaluation of expression of UHRF1 and its prognostic and clinicopathological value in human malignancies: A Systematic Review and Meta-analysis

Evaluation of expression of UHRF1 and its prognostic and clinicopathological value in human malignancies: A Systematic Review and Meta-analysis

CDKN2A promoter methylation enhances self-renewal of glioblastoma stem cells and confers resistance to carmustine

Immune mechanisms and novel therapies for idiopathic pulmonary fibrosis

Contact Info

Product

Resources

About